We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Synthesis and Preclinical Evaluation of Small-Molecule Prostate-Specific Membrane Antigen-Targeted Abiraterone Conjugate.
- Authors
Machulkin, Aleksei E.; Nimenko, Ekaterina A.; Zyk, Nikolay U.; Uspenskaia, Anastasiia A.; Smirnova, Galina B.; Khan, Irina I.; Pokrovsky, Vadim S.; Vaneev, Alexander N.; Timoshenko, Roman V.; Mamed-Nabizade, Vugara V.; Zavertkina, Maria V.; Erofeev, Alexander; Gorelkin, Petr; Majouga, Alexander G.; Zyk, Nikolay V.; Khazanova, Elena S.; Beloglazkina, Elena K.
- Abstract
Prostate cancer is the second most common type of cancer among men. The main method of its treatment is androgen deprivation therapy, which has a wide range of side effects. One of the solutions to this challenge is the targeted delivery of drugs to prostate cancer cells. In this study, we performed the synthesis of a novel small-molecule PSMA-targeted conjugate based on abiraterone. Cytotoxicity, the induction of intracellular reactive oxygen species, and P450-cytochrome species inhibition were investigated for this conjugate PSMA-abiraterone. The conjugate demonstrated a preferential effect on prostate tumor cells, remaining inactive at up to 100 µM in human fibroblast cells. In addition, it revealed preferential efficacy, specifically on PSMA-expressing lines with a 65% tumor growth inhibition level on 22Rv1 (PSMA+) xenografts after 14-fold oral administration of PSMA-Abi at a single dose of 500 mg/kg (7.0 g/kg total dose) was observed. This compound showed significantly reduced acute toxicity with comparable efficacy compared to AbiAc.
- Subjects
ANDROGENS; ORAL drug administration; ANDROGEN deprivation therapy; REACTIVE oxygen species; PROSTATE tumors; PROSTATE cancer
- Publication
Molecules, 2022, Vol 27, Issue 24, p8795
- ISSN
1420-3049
- Publication type
Article
- DOI
10.3390/molecules27248795